A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis

Clinical Rheumatology

Volumn 25, Issue 2, 2006, Pages 205-212

  Nadashkevich, O ^a   Davis, Paul ^b   Fritzler, M ^c   Kovalenko, W ^d  

^a DANYLO HALYTSKY LVIV NATIONAL MEDICAL UNIVERSITY   (Ukraine)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d Institute for Cardiology/Rheumatology   (Ukraine)

Author keywords

Azathioprine; Cyclophosphamide; Systemicsclerosis; Therapy

Indexed keywords

ANTACID AGENT; ANTIBIOTIC AGENT; AZATHIOPRINE; CARBON MONOXIDE; CYCLOPHOSPHAMIDE; DRUG METABOLITE; PREDNISOLONE;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG URINE LEVEL; DYSPEPSIA; ERYTHROCYTE SEDIMENTATION RATE; EXPERIMENTAL DESIGN; FEMALE; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL SYMPTOM; HAIR LOSS; HUMAN; LEUKOPENIA; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NAUSEA; OTITIS MEDIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RAYNAUD PHENOMENON; RESPIRATORY TRACT PARAMETERS; SCORING SYSTEM; SKIN EXAMINATION; STATISTICAL SIGNIFICANCE; SYSTEMIC SCLEROSIS;

ADMINISTRATION, ORAL; ADULT; AGED; AZATHIOPRINE; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PREDNISOLONE; SCLERODERMA, SYSTEMIC;

EID: 33644870428     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-005-1157-y     Document Type: Article

References (25)

1. Sule SD, Wigley FM (2003) Treatment of scleroderma: An update. Expert Opin Investig Drugs 12:471-482
2. Steen VD, Powell DL, Medsger TA Jr (1988) Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 31:196-203
3. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al (1988) Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis. J Rheumatol 12:202-204
4. Pope JE, Bellamy N, Seibold JR, Baron M, Ellman M, Carette S, et al (2001) A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 44:1351-1358
5. Medsger TA Jr, Masi AT (1979) Epidemiology of progressive systemic sclerosis. Clin Rheum Dis 5:15-25
6. Lally EV, Jimenez SA, Kaplan SR (1988) Progressive systemic sclerosis: mode of presentation, rapidly progressive disease course, and mortality based on an analysis of 91 patients. Semin Arthritis Rheum 18:1-13
7. Furst DE, Clements PJ, Hills S, Lachenbruch PA, Miller BL, Sterz MG (1989) Immunosuppression with chlorambucil, versus placebo, for scleroderma: Results of a three-year, parallel, randomized, double-blind study. Arthritis Rheum 32:584-593
8. Jones N, Nadashkevich O, Davis P (1997) A comparison of cyclophosphamide versus azathioprine in the treatment of diffuse systemic sclerosis: results of a pilot open study (abstr). J Rheumatol 24:1426
9. Medsger TA Jr, Steen VD (1996) Classification, prognosis. In: Clements PJ, Furst DE (eds) Systemic sclerosis. Williams & Wilkins, Baltimore, pp 51-64
10. Silver RM, Warrick JH, Kinsella MB, Staudt LS, Bauman MH, Strange C (1993) Cyclophosphamide and low-dose prednisolone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J Rheumatol 20:838-844
11. Akesson A, Scheja A, Lundin A, Woolheim FA (1994) Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide. Arthritis Rheum 37:729-735
12. Steen VD, Lanz JR Jr, Conte C, Owens GR, Medsger TA Jr (1994) Therapy for severe interstitial lung disease in systemic sclerosis: A retrospective study. Arthritis Rheum 37:1290-1296
13. Davas EM, Peppas C, Maragou M, Alvanou E, Hondros D, Dantis PO (1999) Intravenous cyclophosphamide pulse therapy for the treatment of lung disease associated with scleroderma. Clin Rheumatol 18:455-461
14. White B, Moore WC, Wigley FM, Xiao HQ, Wise RA (2000) Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 132:947-954
15. Griffiths B, Miles S, Moss H, Robertson R, Veale D, Emery P (2002) Systemic sclerosis and interstitial lung disease: A pilot study using pulse intravenous methylprednisolone and cyclophosphamide to assess the effect on high resolution computed tomography scan and lung function. J Rheumatol 29:2371-2378
16. Calguneri M, Apras S, Ozbalkan Z, Ertenli I, Kiraz S, Ozturk M (2003) The efficacy of oral cyclophosphamide plus prednisolone in early diffuse systemic sclerosis. Clin Rheumatol 22:289-294
17. Masi AT, Rodnan GP, Medsger TA Jr, Altman RD, D'Angelo WA, Fries JF (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23:581-590
18. Merkel PA, Clements PJ, Reveille JD, Suarez-Almazor ME, Valentini G, Furst DE (2003) Current status of outcome measure development for clinical trials in systemic sclerosis. Report from OMERACT 6. J Rheumatol 30:1630-1647
19. Ramsden MF, Goldsmith CH, Lee P, Sebaldt R, Baer P (1986) Clinical assessment of scleroderma: Observer variation in five methods (abstr). Arthritis Rheum 29:S61
20. Clements P, Lachenbruch P, Seibold J, White B, Weiner S, Martin R (1995) Inter and intraobserver variability of total skin thickness score (Modified Rodnan TSS) in systemic sclerosis 22:1281-1285
21. Mayes MD, O'Donnell, Rothfield NF, Csuka ME (2004) Minocycline is not effective in systemic sclerosis. Arthritis Rheum 50:553-557
22. Wigley F (1998) Systemic sclerosis clinical features. In: Klippel JH, Dieppe PA (eds) Rheumatology. Mosby, Philadelphia, pp 7.9.1-7.9.13
23. Nadashkevich O, Davis P, Fritzler M (2004) A proposal of criteria for the classification of systemic sclerosis. Med Sci Monit (in press)
24. Lee AT, Burnet S (2002) Corticosteroid-induced scleroderma renal crisis. Med J Aust 177:459
25. DeMarco PJ, Weisman MH, Seibold JR, Furst DE, Wong WK, Hurwitz EL, et al (2002) Predictors and outcomes of scleroderma renal crisis: The high-dose versus low-dose d -penicillamine in early diffuse systemic sclerosis trial. Arthritis Rheum 46:2983-2989